Moderna and Vertex Establish New Collaboration to Treat Cystic Fibrosis Using Gene Editing

Second collaboration between Moderna and Vertex based on Moderna’s proprietary mRNA and LNP technology Collaboration will leverage Vertex’s investments and capabilities in genetic technologies for CF Moderna to receive $75 million upfront, with potential for additional development, regulatory and commercial milestones and royalty payments CAMBRIDGE & BOSTON, Mass.--( BUSINESS WIRE )-- M